Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individualizing cancer chemotherapy

Howard L McLeod1

  • 1Washington University, St. Louis, USA.

Clinical Advances in Hematology & Oncology : H&O
|May 27, 2006
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

JCO precision oncology·2026
Same author

Propranolol metabolite and enantiomers affect colorectal cancer development by inhibiting MAPK pathway and downregulating PD-1 expression.

International immunopharmacology·2025
Same author

A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors.

Cancer letters·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025
Same author

Causal effects of immune cells on the efficacy and adverse drug reactions of platinum drugs.

Acta biochimica et biophysica Sinica·2025
Same author

Pharmacogenomics in Oncology-Running Out of Excuses for Slow Adoption.

JAMA network open·2024
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles